1.
Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020.
Allergol Int 2020;69:519-48.
2.
Ichinose M, Sugiura H, Nagase H, et al. Japanese guidelines for adult asthma 2017.
Allergol Int 2017;66:163-89.
3.
Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J
Med 1990;323:1033-9.
4.
Ohashi Y, Motojima S, Fukuda T, Makino S. Airway hyperresponsiveness, increased
intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and
lymphocytes in bronchial mucosa in asthma. Am Rev Respir Dis 1992;145:1469-76.
5.
Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a
roadmap to asthma control. Eur Respir J 2015;46:622-39.
6.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and
the prevention of death from asthma. N Engl J Med 2000;343:332-6.
7.
Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp
Allergy 2012;42:650-8.
8.
Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes.
Am J Respir Crit Care Med 2008;178:218-24.
9.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using
cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med
2010;181:315-23.
10.
Opina MT, Moore WC. Phenotype-Driven Therapeutics in Severe Asthma. Curr
Allergy Asthma Rep 2017;17:10.
11.
Kaneko Y, Masuko H, Sakamoto T, et al. Asthma Phenotypes in Japanese Adults -
Their Associations with the CCL5 ADRB2 Genotypes. Allergology International 2013;62:11321.
12.
COPD 診断と治療のためのガイドライン 2018、日本呼吸器学会 COPD ガイドライン
第 5 版作成委員会、メディカルビュー社 2018.
13.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis,
Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD
Executive Summary. Am J Respir Crit Care Med 2017;195:557-82.
14.
Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden
of Disease Study. Science 1996;274:740-3.
15.
Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD
Epidemiology study. Respirology 2004;9:458-65.
52
16.
Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and
airflow obstruction: 25 years on from the Ciba symposium. Thorax 1984;39:81-5.
17.
Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity
of emphysema in chronic obstructive pulmonary disease. Thorax 2007;62:932-7.
18.
Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients
with COPD. Eur Respir J 2008;31:742-50.
19.
Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management,
and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report
2019. Eur Respir J 2019;53.
20.
Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel
approach using principal component and cluster analyses. Eur Respir J 2010;36:531-9.
21.
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive
pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care
Med 2011;184:662-71.
22.
Barnes PJ. Inflammatory endotypes in COPD. Allergy 2019;74:1249-56.
23.
Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on
the disease phenotypes. Int J Chron Obstruct Pulmon Dis 2015;10:1093-102.
24.
<喘息と COPD オーバーラップ診断と治療の手引き 2018 一般社団法人日本呼吸器学
会喘息と COPD のオーバーラップ（Asthma and COPD Overlap：ACO）診断と治療の手引き
2018 作成委員会
25.
メディカルビュー社 2018.>.
Hizawa N. Genetic Backgrounds of Asthma and COPD. Allergology International
2009;58:8.
26.
Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD
predicts low quality of life. J Asthma 2011;48:279-85.
27.
Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD
(GesEPOC). Update 2014. Arch Bronconeumol 2014;50 Suppl 1:1-16.
28.
Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary
disease, and mortality in the U.S. population. Copd 2011;8:400-7.
29.
de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic
obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and
elderly people from the general population. PLoS One 2013;8:e62985.
30.
Hersh CP, Jacobson FL, Gill R, Silverman EK. Computed tomography phenotypes in
severe, early-onset chronic obstructive pulmonary disease. Copd 2007;4:331-7.
31.
Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic
challenge. Respirology 2016;21:410-8.
53
32.
Orie NG, HJ S, K D. The host factor in bronchitis. . 1961;Orie NG, Sluiter HJ, eds.
Bronchitis. Royal Van Gorcum, Assen, The Netherlands,:43-59.
33.
Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune
response translates respiratory viral infection into chronic lung disease. Nat Med 2008;14:63340.
34.
Borchers MT, Wesselkamper SC, Curull V, et al. Sustained CTL activation by murine
pulmonary epithelial cells promotes the development of COPD-like disease. J Clin Invest
2009;119:636-49.
35.
Orie N SH, DeVries K et al. The host factor in bronchitis. Bronchitis 1961.
36.
Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both "Dutch"
and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin
Immunol 2015;135:63-72.
37.
一般社団法人日本アレルギー学会喘息ガイドライン専門部会監 喘息予防・管理ガイ
ドライン 2015
38.
東京：協和企画；2015.
Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and
budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy
(FACET) International Study Group. N Engl J Med 1997;337:1405-11.
39.
Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between
COPD and asthma. Respir Res 2011;12:127.
40.
Menezes AMB, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation
and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014;145:297304.
41.
de Marco R, Marcon A, Rossi A, et al. Asthma, COPD and overlap syndrome: a
longitudinal study in young European adults. Eur Respir J 2015;46:671-9.
42.
Cosio BG, Soriano JB, López-Campos JL, et al. Defining the Asthma-COPD Overlap
Syndrome in a COPD Cohort. Chest 2016;149:45-52.
43.
Suzuki M, Makita H, Konno S, et al. Asthma-like Features and Clinical Course of
Chronic Obstructive Pulmonary Disease. An Analysis from the Hokkaido COPD Cohort Study.
Am J Respir Crit Care Med 2016;194:1358-65.
44.
Greenblatt RE, Zhao EJ, Henrickson SE, Apter AJ, Hubbard RA, Himes BE. Factors
associated with exacerbations among adults with asthma according to electronic health record
data. Asthma Res Pract 2019;5:1.
45.
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic
obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
46.
Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J
2004;24:822-33.
54
47.
Kim MA, Shin SW, Park JS, et al. Clinical Characteristics of Exacerbation-Prone Adult
Asthmatics Identified by Cluster Analysis. Allergy Asthma Immunol Res 2017;9:483-90.
48.
Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI statement on severe
exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J
2019;54.
49.
Hirai K, Shirai T, Suzuki M, et al. A clustering approach to identify and characterize
the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin Exp Allergy
2017;47:1374-82.
50.
Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in
COPD. Respir Med 2018;138:21-31.
51.
George L, Taylor AR, Esteve-Codina A, et al. Blood eosinophil count and airway
epithelial transcriptome relationships in COPD versus asthma. Allergy 2020;75:370-80.
52.
Ohta K, Bousquet PJ, Aizawa H, et al. Prevalence and impact of rhinitis in asthma.
SACRA, a cross-sectional nation-wide study in Japan. Allergy 2011;66:1287-95.
53.
Kim JK, Lee SH, Lee BH, et al. Factors associated with exacerbation in mild- to-
moderate COPD patients. Int J Chron Obstruct Pulmon Dis 2016;11:1327-33.
54.
Kurashima K, Takaku Y, Ohta C, Takayanagi N, Yanagisawa T, Sugita Y. COPD
assessment test and severity of airflow limitation in patients with asthma, COPD, and asthmaCOPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2016;11:479-87.
55.
Rassouli F, Baty F, Stolz D, et al. Longitudinal change of COPD assessment test
(CAT) in a telehealthcare cohort is associated with exacerbation risk. Int J Chron Obstruct
Pulmon Dis 2017;12:3103-9.
56.
Havemann BD, Henderson CA, El-Serag HB. The association between gastro-
oesophageal reflux disease and asthma: a systematic review. Gut 2007;56:1654-64.
57.
Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and Comorbid Features
of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med
2017;195:302-13.
58.
Kaneko Y, Yatagai Y, Yamada H, et al. The search for common pathways underlying
asthma and COPD. Int J Chron Obstruct Pulmon Dis 2013;8:65-78.
59.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary
disease. J Allergy Clin Immunol 2016;138:16-27.
60.
Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-
Severe Uncontrolled Asthma. N Engl J Med 2018;378:2486-96.
61.
Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma.
Trends Immunol 2012;33:238-46.
55
62.
Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict
reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J
Allergy Clin Immunol 2012;130:516-22 e4.
63.
Sunadome H, Matsumoto H, Petrova G, et al. IL4Ralpha and ADAM33 as genetic
markers in asthma exacerbations and type-2 inflammatory endotype. Clin Exp Allergy
2017;47:998-1006.
64.
GTEx Portal, https://gtexportal.org/home/.
65.
Pullat J, Fleischer R, Becker N, Beier M, Metspalu A, Hoheisel JD. Optimization of
candidate-gene SNP-genotyping by flexible oligonucleotide microarrays; analyzing variations in
immune regulator genes of hay-fever samples. BMC Genomics 2007;8:282.
66.
Shirai T, Mikamo M, Tsuchiya T, et al. Real-world effect of gastroesophageal reflux
disease on cough-related quality of life and disease status in asthma and COPD. Allergol Int
2015;64:79-83.
67.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum
eosinophil counts: a randomised controlled trial. The Lancet 2002;360:1715-21.
68.
Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of
benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase
3 extension trial. The Lancet Respiratory Medicine 2019;7:46-59.
69.
Masuko H, Sakamoto T, Kaneko Y, et al. Lower FEV1 in non-COPD, nonasthmatic
subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP
genotypes. Int J Chron Obstruct Pulmon Dis 2011;6:181-9.
70.
Becg CB, Gray R. Calculation of polychotomous logistic regression parameters using
individualized regressions. Biometrika 1984 ;71: 11-8.
71.
Kitazawa H, Masuko H, Kanazawa J, et al. ORMDL3/GSDMB genotype is associated
with distinct phenotypes of adult asthma. Allergol Int 2021.
72.
Yatagai Y, Sakamoto T, Yamada H, et al. Genomewide association study identifies
HAS2 as a novel susceptibility gene for adult asthma in a Japanese population. Clin Exp Allergy
2014;44:1327-34.
73.
難治性喘息診断と治療の手引き 2019
き 2019 作成委員会
74.
日本呼吸器学会難治性喘息診断と治療の手引
メディカルレビュー社 2019.
Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective
annual asthma disease burden: a UK cohort study. The Lancet Respiratory Medicine 2015;3:84958.
75.
Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J
Chron Obstruct Pulmon Dis 2015;10:1935-49.
56
76.
Mokhlesi B, Morris AL, Huang CF, Curcio AJ, Barrett TA, Kamp DW. Increased
prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001;119:10438.
77.
Lezmi G, Galmiche-Rolland L, Rioux S, et al. Mast cells are associated with
exacerbations and eosinophilia in children with severe asthma. Eur Respir J 2016;48:1320-8.
78.
Bradding P, Arthur G. Mast cells in asthma--state of the art. Clin Exp Allergy
2016;46:194-263.
79.
Wenzel SE, Balzar S, Ampleford E, et al. IL4R alpha mutations are associated with
asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007;175:570-6.
80.
HaploReg, https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php.
81.
Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4
variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of
two phase 2a studies. The Lancet 2007;370:1422-31.
82.
Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R.
Trends in international asthma mortality: analysis of data from the WHO Mortality Database
from 46 countries (1993-2012). Lancet 2017;390:935-45.
83.
Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet
2018;391:350-400.
84.
Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010;376:803-
13.
85.
McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a
severe asthma registry and predict future exacerbations. Respirology 2019;24:37-47.
57
謝辞
本研究を実施するにあたり、終始御懇切なる御指導と御鞭捷を賜りました筑波大学大学
院呼吸器内科檜澤伸之教授に深い謝意を表します。
適切な御指導と御示唆をいただきました筑波大学大学院呼吸器内科増子裕典講師に深く
感謝いたします。
研究その他多方面にわたりご指導いただきました筑波大学大学院遺伝医学野口恵美子教
授、筑波大学附属病院土浦市地域臨床教育センター石井幸雄教授、筑波大学附属病院水戸
地域医療教育センター佐藤浩昭教授、筑波大学附属病院神栖地域医療教育センター家城隆
次元教授、筑波大学附属病院ひたちなか地域医療教育センター山田英恵准教授に深く感謝
いたします。
遺伝子解析で多大なる御協力、御指導をいただきました東京慈恵医科大学総合医科学研
究センター基盤研究施設分子遺伝学玉利真由美教授、広田朝光講師に深謝いたします。
日々の研究において御援助、御協力をいただきました、つくば総合健診センター内藤隆
志センター長をはじめ、つくば総合健診センターのスタッフの皆様に感謝いたします。
遺伝子タイピングをはじめ様々な実験手技を一からご指導いただき、臨床サンプルから
のDNA抽出に技術協力してくださった中村貴子女史に深く感謝いたします。
また、研究において様々な御協力、御教示をいただきました、坂本透病院教授、森島祐
子准教授、松野洋輔講師、際本拓未講師、小川良子講師、増子裕典講師、中澤健介講師、
塩澤利博病院講師、松山政史病院講師、吉田和史病院講師、川口未央医学博士、齋藤武文
医学博士、二宮浩樹医学博士、遠藤健夫医学博士、石川博一医学博士、飯島弘晃医学博
士、野村明広医学博士、長南達也医学博士、金子美子医学博士、谷田貝洋平医学博士、林
士元医学博士、角田義弥医学博士、櫻井啓文医学博士、金澤潤医学博士、中嶋真之医学博
士、北沢晴奈医学博士、Mingma Sherpa医学博士、重政理恵医学士、荒井直樹医学士、秋
58
山達也医学士、野中水医学士、大島央之医学士、薮内悠貴医学士、国立病院機構 茨城東
病院のスタッフの皆様に深謝いたします。
本研究は、日本アレルギー学会臨床研究支援プログラム（2016年度及び2017年度）の支
援を受けて実施しました。研究参加者の募集及びデータ収集にご協力いただいた医師の皆
様に感謝いたします。
59
出典
本学位論文は PLoS One. 2022 Mar 21;17（3）:e0264397.（doi:
10.1371/journal.pone.0264397. eCollection 2022.）に掲載された論文の内容をクリエ
イティブコモンズ（CC BY）ライセンスの規定に準拠して再利用している。
60
...
論文の公開元へ
